This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

CIS001 Extension Study of Cyclosporine Inhalation Solution (CIS002)

This study has been terminated.
(Parent study CIS001 was completed)
Information provided by (Responsible Party):
APT Pharmaceuticals, Inc. Identifier:
First received: July 9, 2009
Last updated: September 13, 2012
Last verified: September 2012
This trial is a longterm follow up of a phase III study of inhaled cyclosporine for the prevention of chronic rejection in lung transplant recipients.

Condition Intervention Phase
Lung Transplant Drug: Cyclosporine Inhalation Solution (CIS) Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: CIS002: An Open-Label, Multi-Center, Extension Study of Cyclosporine Inhalation Solution in Subjects Previously Enrolled in the APT Study CIS001

Resource links provided by NLM:

Further study details as provided by APT Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • To assess the long-term safety of CIS administration [ Time Frame: 5 years ]

Enrollment: 17
Study Start Date: December 2009
Study Completion Date: December 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Inhaled cyclosporine
Extended access to inhaled cyclosporine for patients from treatment and control arms of Phase 3 study CIS001
Drug: Cyclosporine Inhalation Solution (CIS)
Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Enrollment in study CIS001
  2. Written informed consent for CIS002
  3. Use of an effective means of contraception by women of childbearing potential

Exclusion Criteria:

  1. Any unresolved or irreversible CIS-related ongoing serious adverse event
  2. Subjects who have developed newly emergent conditions, injuries, diagnoses, physical examination findings, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk of treatment complications
  3. Subjects with suspected or documented allergy to propylene glycol and/or cyclosporine
  4. Women who are pregnant, wishing to become pregnant, or unwilling to use appropriate birth control to avoid becoming pregnant
  5. Women who are breastfeeding
  6. Subjects unable to comply with all protocol requirements and follow-up procedures
  7. Subjects who discontinued from CIS002 to participate in another clinical trial and have received any investigational treatment (other than CIS) within 14 days of titration visit 1/baseline.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00938236

United States, California
UCLA School of Medicine
Los Angeles, California, United States, 90095
University of California, San Francisco
San Francisco, California, United States, 94143
Stanford University Medical Center
Stanford, California, United States, 94305
United States, Colorado
University of Colorado Health Sciences Cente
Denver, Colorado, United States, 80262
United States, Florida
University of Florida Health Sciences Center
Gainesville, Florida, United States, 32610
Tampa General Hospital
Tampa, Florida, United States, 33601
United States, Illinois
Loyola University Hospital
Maywood, Illinois, United States, 60153
United States, Indiana
Indiana Methodist Research Institute
Indianapolis, Indiana, United States, 46202
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, New York
New York Presbyterian Hospital, Columbia University Med. Ctr.
New York, New York, United States, 10032
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
Baylor College of Medicine
Houston, Texas, United States, 77030
United States, Virginia
Inova Fairfax Hospital
Falls Church, Virginia, United States, 22402
Canada, Ontario
University of Toronto
Toronto, Ontario, Canada, M5G 2N2
Sponsors and Collaborators
APT Pharmaceuticals, Inc.
Principal Investigator: Bruce A Johnson, MD University of Pittsburgh
Principal Investigator: Jeffrey Golden, MD University of California, San Francisco
  More Information

Additional Information:

Responsible Party: APT Pharmaceuticals, Inc. Identifier: NCT00938236     History of Changes
Other Study ID Numbers: CIS002
Study First Received: July 9, 2009
Last Updated: September 13, 2012

Keywords provided by APT Pharmaceuticals, Inc.:
lung transplant
lung transplant recipient
bronchiolitis obliterans syndrome
bronchiolitis obliterans
single lung transplant
double lung transplant
heart-lung transplant

Additional relevant MeSH terms:
Pharmaceutical Solutions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors processed this record on September 21, 2017